Lomustine (CCNU)

/content/dataitem/canine-and-feline/lomustine

Lomustine (CCNU)

Online Access: Subscribe

This is a drug monograph from the BSAVA Small Animal Formulary Part A: Canine and Feline. BSAVA members should login for access to the full monograph. Non-members can join BSAVA, buy a Formulary subscription, or buy the printed edition.

Kristal O ,Rassnick KM ,Gliatto JM et al.(2004)Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. Journal of Veterinary Internal Medicine 18 ,75–80

Skorupski KA ,Hammond GM ,Irish AM et al. (2011)Prospective Randomized Clinical Trial Assessing the Efficacy of Denamarin for Prevention of CCNU-Induced Hepatopathy in Tumor-Bearing Dogs. Journal of Veterinary Internal Medicine 25 ,838–845

Heading KL, Brockley LK and Bennett PF (2011) CCNU (lomustine) toxicity in dogs: a retrospective study (2002–07). Australian Veterinary Journal 89, 109–116

Moore AS, London CA, Wood CA et al. (1999) Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.Journal of Veterinary Internal Medicine 13, 395–398

Rassnick KM, Moore AS, Williams LE et al.(1999) Treatment of canine mast cell tumors with CCNU (lomustine).Journal of Veterinary Internal Medicine 13, 601–605

Rau SE and Burgess KE (2017) A retrospective evaluation of lomustine (CeeNU) in 32 treatment naïve cats with intermediate to large cell gastrointestinal lymphoma (2006–2013)Veterinary and Comparative Oncology 15, 1019–1028

Risbon RE, de Lorimier LP, Skorupski K et al.(2006) Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999–2004).Journal of Veterinary Internal Medicine 20, 1389–1397